Biopartners Terminates Collaboration with The Medical House

Biopartners Holdings AG today announced that it has terminated its
supply agreement with The Medical House. In February 2005, The Medical
House signed a 10 year supply agreement with Biopartners GmbH for the
license and supply of The Medical House´s GH1 reusable, spring
powered, needle-free delivery system for the delivery of Biopartners´
human growth hormone product, Valtropin(R).

In 2006 Biopartners initiated a comparative
bioavailability/bioequivalence study in volunteers to assess Valtropin
delivered by The Medical House´s GH1. The Medical House has never been
able to supply Biopartners with the GH1 devices needed to perform this
clinical study. Therefore, Biopartners terminated the collaboration.

"Having received EMEA approval in April 2006, we had planned to
launch Valtropin at the end of that year" commented Mr Jean-Noel
Treilles, CEO of Biopartners. "However, with the GH1 device not
functioning correctly, we have had to end our agreement with The
Medical House in order to seek a suitable and robust alternative
delivery system."

About Biopartners Holdings AG

Headquartered in Baar, Switzerland, with an affiliate in Germany,
Biopartners is a global biopharmaceuticals company and a leader in the
emerging field of multi-source biopharmaceuticals. Biopartners´
mission is to develop biopharmaceuticals and innovative formulations
of "first generation" biopharmaceuticals as well as advanced delivery
systems that may improve patient compliance. Biopartners is developing
a comprehensive range of biopharmaceutical products that may offer
life-saving therapeutic benefits across many therapeutic areas.
Biopartners has submitted three dossiers to the EMEA and has a fourth
product in phase III on the way. In March 2007, Biopartners was
acquired by a Polish biotechnology company, Bioton S.A.